ReviewJournal of personalized medicine2024
Neuroinflammation and Schizophrenia: New Therapeutic Strategies through Psychobiotics, Nanotechnology, and Artificial Intelligence (AI).
Review in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Translational interdisciplinary research on human chorionic gonadotropin's enhancement of neuroendocrine crosstalk: a novel medical hypothesis for systemic adjunctive treatment of psychiatric disorders.Frontiers in psychiatry · 2025Pooled it
- Pooled it
- Effectiveness of Psychobiotics in the Treatment of Psychiatric and Cognitive Disorders: A Systematic Review of Randomized Clinical Trials.Nutrients · 2024Pooled it
- The use of artificial intelligence in psychotherapy: development of intelligent therapeutic systems.BMC psychology · 2025Trial
- Exploring comorbidity patterns of psychosis-related post-traumatic stress disorder and depression symptoms in stabilised hospitalised schizophrenia patients and relationships with sleep quality and quality of life: a latent profile analysis.European journal of psychotraumatology · 2026Article
- Silent Inflammation: A Critical Narrative Review of the Relationship Between Periodontal Disease and Psychosis-The Role of Oxidative Stress and Iatrogenic Comorbidities.Antioxidants (Basel, Switzerland) · 2026Review
- Janus kinase/signal transducer and activator of transcription pathway in schizophrenia (Review).Biomedical reports · 2026Review
- MicroRNAs as biomarkers and molecular mediators of cognitive dysfunction in schizophrenia.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Integrating Gut-Brain Axis: Exploring the Neurogastrointestinal Interactions and Therapeutic Potentials in Autism Spectrum Disorder.Endocrine, metabolic & immune disorders drug targets · 2026Review
- A comprehensive review on schizophrenia: epidemiology, pathogenesis, diagnosis, conventional treatments, and proposed natural compounds used for management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Effects of Virtual Reality on Motor Function and Balance in Incomplete Spinal Cord Injury: A Systematic Review and Meta-Analysis of Controlled Trials.Brain sciences · 2025Review
- Discovering a new paradigm: Gut microbiota as a central modulator of sexual health.World journal of gastrointestinal pathophysiology · 2025Review
- Psychobiotics in Aquaculture: Harnessing the Microbiome-Gut-Brain Axis for Stress Management and Production Enhancement in Fish.Animals : an open access journal from MDPI · 2025Review
- Large-Scale Meta-Analysis of TNF-α rs1800629 Polymorphism in Schizophrenia: Evidence from 7,624 Cases and 8,933 Controls.Medeniyet medical journal · 2025Article
- Shaping the Future of Psychiatric Neurosurgery: From Connectomic Precision to Technological Integration.Brain sciences · 2025Review
- Nutraceuticals: a promising, yet unregulated Frontier in Healthcare.European journal of clinical nutrition · 2025Review
- KEAP1-NRF2/HO-1 Pathway Promotes Ferroptosis and Neuronal Injury in Schizophrenia.Brain and behavior · 2025Article
- Should we consider microbiota-based interventions as a novel therapeutic strategy for schizophrenia? A systematic review and meta-analysis.Brain, behavior, & immunity - health · 2025Article
- The impact of artificial intelligence on drug discovery for neuropsychiatric disorders.EXCLI journal · 2025Review
- Pathogenic synergy: dysfunctional mitochondria and neuroinflammation in neurodegenerative diseases associated with aging.Frontiers in aging · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The prevalence of schizophrenia, affecting approximately 1% of the global population, underscores the urgency for innovative therapeutic strategies. Recent insights into the role of neuroinflammation, the gut-brain axis, and the microbiota in schizophrenia pathogenesis have paved the way for the exploration of psychobiotics as a novel treatment avenue. These interventions, targeting the gut microbiome, offer a promising approach to ameliorating psychiatric symptoms. Furthermore, advancements in artificial intelligence and nanotechnology are set to revolutionize psychobiotic development and application, promising to enhance their production, precision, and effectiveness. This interdisciplinary approach heralds a new era in schizophrenia management, potentially transforming patient outcomes and offering a beacon of hope for those afflicted by this complex disorder.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.